96417 — chemotherapy administration, intravenous infusion technique; each additional sequential infusion of a different substance, up to 1 hour (list separately in addition to the primary procedure code). It reports the second, third, or fourth distinct chemo drug given at the same encounter after the initial chemo administration. It is an add-on code: it cannot stand alone and must follow a 96413 (initial infusion) or 96409 (initial push) at the same encounter. 96417 is for a different drug; additional time on the same drug uses 96415; concurrent infusion of a different drug uses 96416.
96417 lives in the AMA CPT 96401-96549 chemotherapy and other highly complex drug or highly complex biologic agent administration family. Authority is the current-year AMA CPT Professional Edition; sequencing and edit policy are in the NCCI Policy Manual Chapter XI, which restates the “one initial code per encounter, additional substances use add-on codes” rule and assigns Medically Unlikely Edit caps.
96417 was created to solve a problem: multi-drug chemo regimens (R-CHOP, FOLFOX, FOLFIRINOX, ABVD, BEP, paclitaxel + carboplatin) routinely involve three to five distinct drugs administered in one chair-time visit, and AMA CPT permits only one initial-administration code per encounter. 96417 captures the additional drugs without inflating the initial code count. Each additional sequential chemo substance gets one unit of 96417, regardless of that drug's individual infusion duration — though if the additional drug itself runs longer than an hour, additional 96415 units are reported on top of the 96417 line (96415 is the hour-extension add-on for either 96413 or 96417).
Because 96417 is an AMA add-on code (designated with the + symbol), it is exempt from most NCCI Procedure-to-Procedure edits and does not require modifier 59 to be billed alongside its parent. Submitting 96417 without a primary code on the same encounter is the most common rejection.
The 96417/96415/96416 distinction is the single most error-prone judgment call in chemo administration coding. The mental model that helps: 96415 answers “more time?”; 96417 answers “new drug, after the previous one finished?”; 96416 answers “new drug, running alongside another?”. In practice the great majority of multi-drug oncology encounters are sequential (96417 territory) because compatibility, sterility, and infusion-pump logistics push regimens toward back-to-back rather than simultaneous administration.
The single largest source of 96417 denials is misuse for additional time on the same drug. A 3-hour rituximab infusion is 96413 + 96415 x 2 — not 96413 + 96417. The 96417 line is reserved for the next distinct chemo substance, and most payer edits will reject 96417 if there is only one NDC on the claim.
96417 is an AMA CPT construct that all major payers honor. Divergence shows up in two narrow places: a few commercial payer audit programs scrutinize 96417 unit counts above 3 (R-CHOP at 3, FOLFIRINOX at 3-4 depending on whether the continuous 5-FU pump is sequential or initialization-only), and prior-authorization decisions for some multi-drug regimens explicitly approve the expected 96417 unit count up front to prevent claim-line disputes.
| Payer | Aligned with AMA hierarchy? | Notes |
|---|---|---|
| Medicare (Part B) | Yes | Source-of-truth payer. NCCI Policy Manual Ch.XI restates the “additional sequential substances = 96417” rule. MUE caps the practitioner-billed unit count; edit cycle rejects 96417 lacking a same-date primary (96413 or 96409). |
| UnitedHealthcare | Yes | Aligns with CMS at adjudication. OptumRx oncology PA approvals frequently list the expected administration-code structure (initial + N additional sequential) on the PA letter so that claim coding aligns with PA approval. |
| Aetna (CVS Health) | Yes | Aligns with CMS. Aetna oncology medical policies reference the chemo administration family; multi-drug regimens (R-CHOP, FOLFOX, FOLFIRINOX) have policy bulletins that cite the expected admin-code stack. |
| Cigna / Express Scripts | Yes | Aligns with CMS. Accredo specialty pharmacy ships chemo product directly to the practice for buy-and-bill. Cigna oncology medical policies are explicit about indication-driven administration coding. |
| Humana | Yes | MA-heavy book follows CMS by default. CenterWell Specialty supplies oncology chemo for Humana MA. Humana commercial PPO aligns to AMA hierarchy with same enforcement posture as Medicare. |
| Denial pattern | What it means | Fix / appeal language |
|---|---|---|
| 96417 billed without 96413 or 96409 primary (CARC 107) | Add-on code submitted on its own line without an initial chemo administration code on the same encounter. NCCI rejects add-on codes that lack their primary procedure. | Add the appropriate primary — 96413 if the first chemo drug was an infusion, 96409 if it was an IV push. Appeal language: “96417 is an AMA add-on code that must be reported in conjunction with a chemo administration primary (96413 for initial infusion or 96409 for initial push) on the same encounter. The corrected claim adds the 96413/96409 primary for the first chemo administration of the visit.” |
| 96417 used for additional time on same drug (CARC 16) | Single chemo drug ran longer than 1 hour and was coded as 96413 + 96417 rather than 96413 + 96415. 96417 is for an additional substance, not for additional time on the same substance. | Rebill with 96413 + 96415 x N. Appeal language: “Per AMA CPT 96401-96549 introductory guidelines, 96415 reports each additional hour of a chemo IV infusion of the same substance. 96417 reports each additional sequential substance. The encounter administered a single substance ([drug, J-code]) for [N] hours; the corrected claim reports 96413 + 96415 x [N-1].” |
| 96417 used for concurrent infusion (CARC 16) | Two chemo drugs ran simultaneously through separate lines or piggy-back, and the second drug was coded as 96417 rather than 96416. 96417 is sequential; 96416 is concurrent. | Rebill with 96416 for the concurrent additional drug. Appeal language: “Per AMA CPT, 96417 is reported for sequential additional chemo substances (back-to-back through the same line). 96416 is reported for concurrent additional chemo substances (simultaneous through separate lines or piggy-back). The medical record documents concurrent administration of [drug 1] and [drug 2] from [start] to [stop]; the corrected claim reports 96416 for the concurrent drug.” |
| 96417 exceeds MUE (CARC 151) | Unit count on 96417 exceeds the CMS Medically Unlikely Edit cap. Most multi-drug regimens cap at 3-4 additional sequential substances per encounter. | Verify the regimen requires the reported unit count and that each substance is documented in the chart with start/stop times. If clinically appropriate, submit with modifier-supported documentation or appeal with the regimen reference (e.g., NCCN guideline for R-CHOP at 3 additional substances). Appeal language: “The encounter administered [N] distinct chemo substances sequentially per the [NCCN regimen / treatment plan]. Start and stop times for each substance are documented in the medical record at [chart reference]. The reported 96417 units reflect distinct sequential substances, each requiring separate administration.” |
| 96417 reported for pre-medication (CARC 11 / 96) | Anti-emetic, antihistamine, or steroid pre-medication coded as 96417 instead of 96375 (sequential push) or 96367 (sequential infusion). Pre-medications are not chemo per the AMA family definition. | Rebill the pre-medication line as 96375 (push) or 96367 (infusion). Appeal language: “[Drug] is a [anti-emetic / antihistamine / steroid] pre-medication, not a chemotherapy or highly complex biologic agent. Per AMA CPT, it is reported under the therapeutic family — 96375 for sequential IV push or 96367 for sequential therapeutic infusion. The corrected claim restructures the pre-medication line accordingly.” |
96417 = each additional sequential chemo drug at the same encounter (the second drug after the first finishes). 96415 = additional hour(s) of time on the SAME chemo drug (use this when one chemo infusion runs more than 60 minutes). 96416 = concurrent additional chemo drug (two drugs running through separate lines or piggy-backed at the same time). Pick by asking: same drug or new drug? If new drug, sequential or concurrent?
R-CHOP for DLBCL is rituximab (R), cyclophosphamide (C), doxorubicin (H), vincristine (O), prednisone (P). Same-day IV portion: 96413 for rituximab (initial infusion), 96415 for additional rituximab hours, 96417 for each subsequent sequential chemo drug (cyclophosphamide infusion, doxorubicin IV push, vincristine IV push). Prednisone is oral and not billed under administration codes. Pre-meds go on 96375 sequential push lines, not 96417 — those are not chemo.
No. 96417 is an AMA add-on code that must follow an initial chemo administration on the same encounter — either 96413 (initial infusion) or 96409 (initial IV push). Submitting 96417 by itself triggers a CARC 107 add-on-without-primary denial. If the first chemo drug ran by infusion, the primary is 96413; if the first chemo drug was an IV push, the primary is 96409.
No. 96417 is for a DIFFERENT substance. If the same chemo drug runs for an extended time, use 96415 for each additional hour of that same drug. If the same drug is given as both an infusion and a push at the same encounter (unusual — typically a load + maintenance pattern), document the clinical rationale and consult payer policy; many payers will treat the second administration as additional time on the same drug, not a sequential second drug.
No. Pre-medications (anti-emetics like ondansetron and dexamethasone, antihistamines like diphenhydramine, acetaminophen, H2 blockers) are not chemotherapy and use the therapeutic family codes — 96365/96366 for infusion, 96374/96375 for IV push. They are sequential substances to the chemo drug but they do not occupy a 96417 line. The chemo drug itself is the only line that uses 96417.
Sequential = back-to-back through the same line (one drug finishes, the next drug starts; no time overlap). Concurrent = simultaneous infusion of two drugs, either through two separate lines or one piggy-backed into the other while both run. Most chemo regimens are sequential because of compatibility, sterility, and infusion-pump logistics. Concurrent administration is uncommon and usually only seen with continuous-infusion drugs running alongside a bolus.
Generally no. 96417 is an AMA add-on code and add-on codes are exempt from most NCCI Procedure-to-Procedure edits, so modifier 59 is not routinely required when 96417 follows a 96413 or 96409 primary at the same encounter. Modifier 59 may be needed in narrow cases involving separately identifiable encounters on the same calendar day or distinct treatment sessions — but as a routine practice, do not append 59 to 96417.
One unit per additional sequential chemo drug. The CMS Medically Unlikely Edit (MUE) for 96417 caps practitioner-billed units; the most current edit table should be consulted, but in practice three or four additional chemo drugs at one encounter is the realistic ceiling (matching regimens like R-CHOP). If a regimen calls for more, document each drug's start and stop time in the chart and verify the MUE before submitting. Each 96417 unit represents one distinct additional substance — not multiple doses of the same substance.
All sources are publicly available federal publications or paraphrased from AMA / NCCN / trade-association educational materials. AMA CPT code descriptors are reproduced under fair-use reference; full descriptors require an AMA CPT license. The methodology by which we resolve source disagreements is described in the Methodology.